GlassScriptPhysician profile
Mohamed M Haq
NPI 1326011347
$4,504.27
in general payments reported to CMS, 2019-2025
42 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,459 · 2020: $375 · 2021: $74.18 · 2022: $35.87 · 2023: $344 · 2024: $694 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.42 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $364.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $327.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $310.06 | 2019-2025 | Opdualag, Opdivo |
| Celgene Corporation | $292.56 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $290.43 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $250.28 | 2019-2024 | Darzalex |
| Genentech USA, INC. | $225.13 | 2019 | |
| Sobi, INC | $206.12 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $200.44 | 2019-2024 | Somatuline Depot, Onivyde, Tazverik |
| Lilly USA, LLC | $188.05 | 2019-2024 | Retevmo, Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $185.25 | 2019-2025 | Imfinzi, Calquence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.76 | 2019 | |
| Emd Serono, INC. | $119.39 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $104.99 | 2019-2024 | Tavalisse, Rezlidhia |
| Sirtex Medical INC | $102.16 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.